product

Description

HFNC is a promising novel oxygen delivery device, whose mechanisms of action offer some beneficial effects over conventional oxygen systems. It is considered to have a number of physiological effects: it improves oxygenation, dynamic lung compliance, homogeneity and end expiratory lung volume; it decreases anatomical dead space and generates a positive airway pressure that can reduce respiratory rate, the work of breathing, and enhance patient comfort.

Humidified high flow nasal cannula therapy is a form of non-invasive respiratory support which has been compared to continuous positive airway pressure (CPAP).

Application

When HFNC is used to deliver oxygen, the flow rates are much higher than can be achieved with traditional nasal cannula. This results in a greater delivery of prescribed oxygen into the lungs, and less entrainment of room air. The oxygen you want to deliver to your patients is not prone to the same effect of dilution! 

The main physiological effects of HFNC are maintenance of a known stable alveolar FiO2, optimal humidification of the airway mucosa, reduction of the dead space, generation of a positive end-expiratory pressure (PEEP), ultimately yielding a reduction in the respiratory drive and in the work of breathing.

Advantage

In the battle against Covid-19 in Wuhan in 2020, 70% high-flow device was from micomme.

In 2020, micomme ranked the sixth in export of medical respiratory devices in China.

Built-in oxygen-gas mixture to accurately control oxygen and adjust oxygen concentration.

Unique one-way airway design, no need for disinfection, reducing equipment turnover time and the workload of medical staff.

 Intelligent water-controlling system, automatically maintaining the optimal water level in the water chamber.

Specification